AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

From the first glimmer of insight in 1941, when Professor Charles Huggins discovered the hormone dependence of prostate cancer, to today’s flourishing era of precision oncology, the field of genitourinary cancers has traveled an extraordinary path—from silence and therapeutic limitation to an age of precision-driven breakthroughs. As both a participant in and witness to this journey, I feel deeply honored and profoundly inspired.
The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference brought together leading experts, investigators, and innovators to review the latest progress in genitourinary oncology research in China. Alongside academic forums and international expert discussions, the meeting also released the 2025 Annual Report on Chinese Genitourinary Oncology Clinical Research, offering a comprehensive overview of the field’s recent development.
J Pathology | Prof. Guoliang Yang and Prof. Xianbin Su Reveal the Molecular Landscape and Cellular Origins of Bladder Squamous Cell Carcinoma

J Pathology | Prof. Guoliang Yang and Prof. Xianbin Su Reveal the Molecular Landscape and Cellular Origins of Bladder Squamous Cell Carcinoma

Squamous cell carcinoma (SCC) of the bladder is a rare but highly aggressive malignancy associated with poor clinical outcomes and limited responsiveness to conventional therapies. Recently, Professor Guoliang Yang’s team from Renji Hospital, Shanghai Jiao Tong University School of Medicine, together with Professor Xianbin Su’s group from the Institute of Systems Biomedicine at Shanghai Jiao Tong University, published a landmark study in the Journal of Pathology titled “Cellular origins and etiological factors for squamous cell carcinoma and related cancer types of the bladder.”
CSCO Guideline Preview | Professor Hao Zeng Interprets the 2026 CSCO Prostate Cancer Guidelines: Advancing Precision Oncology for Chinese Patients

CSCO Guideline Preview | Professor Hao Zeng Interprets the 2026 CSCO Prostate Cancer Guidelines: Advancing Precision Oncology for Chinese Patients

As one of the most common malignancies affecting men worldwide, prostate cancer requires continuously evolving diagnostic and therapeutic strategies. With rapid advances in precision medicine and the growing body of high-quality clinical evidence generated from Chinese patient populations, the 2026 CSCO Guidelines for Prostate Cancer introduce major updates aimed at better addressing the biological characteristics and clinical needs of patients in China.